Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

Sonelokimab, adalimumab, lutikizumab, and bimekizumab are the top-rated treatments for moderate-to-severe HS, a network ...

Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the treatment, but they regained control upon restarting it.

Non-infectious uveitis is a rare immune-mediated condition in children and is often treated with the tumor necrosis factor inhibitor adalimumab. Discontinuing the drug may be considered when ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

A slew of biosimilar versions of TNF-alpha inhibitor adalimumab will finally arrive on the U.S. market in 2023, almost seven years after the first such molecule, Amgen Inc.’s Amjevita (adalimumab-atto ...

Dr Oskouei explains the indications for adalimumab and the impact of their extrapolation, as well as differences among adalimumab products.

The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for th ...

Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and Bioventure. Alvotech and Bioventure, a wholly owned subsidiary of ...

Another adalimumab biosimilar developed by Boehringer Ingelheim, trade-named Cyltezo, gained interchangeability status last October, but its trial was conducted in psoriasis patients.

A slew of biosimilar versions of the TNF-alpha inhibitor adalimumab will finally arrive on the U.S. market in 2023, almost seven years after the first such molecule, Amgen Inc.’s Amjevita ...